Johnson & Johnson Says European Commission Approves AKEEGA For BRCA1/2-Mutated Prostate Cancer
ReutersMar 9, 2026 5:07 PM
March 9 (Reuters) - Johnson & Johnson JNJ.N:
J&J - EUROPEAN COMMISSION APPROVES AKEEGA FOR BRCA1/2-MUTATED PROSTATE CANCER
Source text: [ID:]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Jensen Huang’s Bold Message: DRAM Fabs Should Expand, Nvidia Will Buy It All.
TradingKey - Nvidia (NVDA) CEO Jensen Huang recently delivered a powerful signal to global memory chip manufacturers at the Morgan Stanley Technology Conference: expand production with confidence, as Nvidia will take all available supply.TradingKey
9 hours ago
Nasdaq Goes "Limitless" on BTC ETF — But the Market Says No
Nasdaq stock unlocks were overshadowed by Middle East tensions; capital continues to flow into the crude oil market, while Bitcoin prices lack key support.TradingKey
11 hours ago
Oil Surges 30% Past $100 as Wall Street Warns of Record Highs
TradingKey - Oil prices surged at the market open on Monday (March 9). Intraday, WTI crude oil futures spiked more than 30% to $118.7 per barrel, while Brent crude oil futures rose over 26%, hitting a high of $119.46 per barrel. This marks the first time international oil prices have broken above $1TradingKey
14 hours ago
The Week on Wall Street: Oil Spikes, VIX Surges, and the Return of the Inflation Scare
TradingKey - Macroeconomic Landscape: The week was significantly influenced by escalating geopolitical tensions in the Middle East, which redirected global market sentiment towards risk aversion. This led to a notable rise in crude oil prices due to fears of supply disruptions through the Strait ofTradingKey
18 hours ago
